SCHOLAR ROCK HOLDING CORP (SRRK)
US80706P1030 - Common Stock
SRRK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. The financial health of SRRK is average, but there are quite some concerns on its profitability. SRRK is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
SRRK had negative earnings in the past year.
In the past year SRRK has reported a negative cash flow from operations.
SRRK had negative earnings in each of the past 5 years.
SRRK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SRRK's Return On Assets of -53.30% is in line compared to the rest of the industry. SRRK outperforms 46.76% of its industry peers.
SRRK has a Return On Equity (-73.62%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.3% | ||
| ROE | -73.62% | ||
| ROIC | N/A |
ROA(3y)-44.72%
ROA(5y)-36.48%
ROE(3y)-67.3%
ROE(5y)-56.04%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SRRK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SRRK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRRK has more shares outstanding
Compared to 5 years ago, SRRK has more shares outstanding
The debt/assets ratio for SRRK is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.11 indicates that SRRK is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.11, SRRK is doing good in the industry, outperforming 77.30% of the companies in the same industry.
SRRK has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
SRRK has a worse Debt to Equity ratio (0.22) than 67.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.11 |
ROIC/WACCN/A
WACC9.17%
2.3 Liquidity
A Current Ratio of 8.80 indicates that SRRK has no problem at all paying its short term obligations.
SRRK's Current ratio of 8.80 is fine compared to the rest of the industry. SRRK outperforms 76.45% of its industry peers.
A Quick Ratio of 8.80 indicates that SRRK has no problem at all paying its short term obligations.
With a decent Quick ratio value of 8.80, SRRK is doing good in the industry, outperforming 76.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.8 | ||
| Quick Ratio | 8.8 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 12.72% over the past year.
SRRK shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)12.72%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-8.7%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, SRRK will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.60% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-5.51%
EPS Next 2Y0.48%
EPS Next 3Y14.01%
EPS Next 5Y15.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SRRK. In the last year negative earnings were reported.
Also next year SRRK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SRRK's earnings are expected to grow with 14.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.48%
EPS Next 3Y14.01%
5. Dividend
5.1 Amount
SRRK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SCHOLAR ROCK HOLDING CORP
NASDAQ:SRRK (5/1/2024, 4:20:01 PM)
After market: 15.12 +0.16 (+1.07%)14.96
+0.29 (+1.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.16B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.3% | ||
| ROE | -73.62% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.8 | ||
| Quick Ratio | 8.8 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)12.72%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-5.51%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y